MK-2206

N/A

Report date: 2024/07/05 11:14:46
NME

Base Information

Drug NameMK-2206
Drug Alias NameNSC-749607MK2206MK-2206BIND-2206
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase AKT1 inhibitors
TargetsSerine/threonine-protein kinase AKT1
Therapy Area/IndicationsChronic eosinophilic leukemia (CEL)Blastic Plasmacytoid Dendritic Cell NeoplasmSkin Melanoma +[90] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesDana-Farber Cancer InstituteChinese University Of Hong Kong (Cuhk)France National Cancer Institute +[4] 
Active IndicationsSkin MelanomaSolid tumoursProstatic Neoplasms +[7] 
Inactive IndicationsChronic eosinophilic leukemia (CEL)Blastic Plasmacytoid Dendritic Cell NeoplasmAngioimmunoblastic T-cell Lymphoma +[83] 

Other Information

ATC CodeN/A
Related LinksWikipedia